{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","spread":"2.00","value":"4.48"},{"groupId":"OG001","spread":"2.12","value":"3.06"}]}],"title":"General Symptom Factor"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"1.29","value":"1.92"},{"groupId":"OG001","spread":"2.45","value":"1.76"}]}],"title":"Gastrointestinal Symptoms Factor"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"2.60","value":"6.23"},{"groupId":"OG001","spread":"2.62","value":"3.39"}]}],"title":"HNC Symptoms"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"1.81","value":"3.55"},{"groupId":"OG001","spread":"2.05","value":"1.60"}]}],"title":"HNC Treatment-Related Symptoms"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"1.70","value":"3.88"},{"groupId":"OG001","spread":"2.12","value":"2.75"}]}],"title":"General Cancer Related Symptoms"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"1.92","value":"4.58"},{"groupId":"OG001","spread":"1.84","value":"2.37"}]}],"title":"Head and Neck Cancer Related Symptoms"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"2.18","value":"6.42"},{"groupId":"OG001","spread":"2.66","value":"4.45"}]}],"title":"Symptoms Interference with Daily Activities"}],"denoms":[{"counts":[{"groupId":"OG000","value":"4"},{"groupId":"OG001","value":"7"}],"units":"Participants"}],"description":"This outcome will report the quality of life questionnaire, the M. D. Anderson symptom inventory head neck (MDASI-HN) at the Post-Operation Visit. This was assessed up to 29 days after surgery (up to 32 days after initiation of study treatment).\n\nMDASI-HN is a 28-question, 2-part questionnaire for patients with head and neck cancer that assesses the severity of symptoms and impact on daily life. In Part I, subjects indicated how severe their symptoms were from \"0 Not present\" to \"10 As Bad as You can Imagine\". In Part II, subjects indicated how symptoms have interfered with their live from \"0 Did not Interfere\" to \"10 Interfered Completely\".\n\nThis assessment was scored according to the The M. D. Anderson Symptom Inventory User Guide.","dispersionType":"Standard Deviation","groups":[{"description":"Patients received celecoxib PO or via feeding tube BID starting 1 to 7 days prior to surgery and continued until the completion of radiation therapy (up to 6 months in total) in the absence of disease progression or unacceptable toxicity.\n\nCelecoxib: Given PO or via feeding tube\n\nQuality-of-Life Assessment: Ancillary studies\n\nQuestionnaire Administration: Ancillary studies","id":"OG000","title":"Celecoxib Arm"},{"description":"Patients received placebo PO or via feeding tube BID starting 1 to 7 days prior to surgery and continued until the completion of radiation therapy (up to 6 months in total) in the absence of disease progression or unacceptable toxicity.\n\nPlacebo: Given PO or via feeding tube\n\nQuality-of-Life Assessment: Ancillary studies\n\nQuestionnaire Administration: Ancillary studies","id":"OG001","title":"Placebo Arm"}],"paramType":"MEAN","populationDescription":"One participant on Arm 1 withdrew consent from the study treatment before the Post-Operation visit and was not evaluable for this endpoint.","reportingStatus":"POSTED","timeFrame":"Up to 29 days after surgery (up to 32 days after initiation of study treatment)","title":"To Assess the Effect of Celecoxib Therapy on the MDASI-HN Questionnaire Compared to Placebo.","type":"SECONDARY","unitOfMeasure":"points"}